Skip to content

Performance and Safety Assessment of T2769 in Contact Lens Wearers With Dry Eye Symptoms.

Performance and Safety Assessment of T2769 in Contact Lens Wearers With Dry Eye Symptoms.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05931861
Enrollment
34
Registered
2023-07-05
Start date
2023-08-15
Completion date
2023-12-04
Last updated
2025-01-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dry Eye

Brief summary

This is a confirmatory clinical investigation. The objective is to collect new additional clinical data demonstrating the safety and performance of the device in the contact-lens wearing population with dry eyes. The hypotheses are that T2769 improves dry eye symptomatology (e.g. decrease in CLDEQ-8 score, in OSDI score, ocular discomfort assessed by VAS) and signs (e.g. increase in Schirmer and TBUT, decrease in Oxford score) at D36, in comparison to baseline. The primary objective of this investigation is to assess the performance of T2769 in contact lens wearers with dry eye symptoms in terms of change from baseline (Day 1) to Day 36 (Final visit) in Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8) total score.

Interventions

DEVICET2769

T2769: sodium hyaluronate 0.15%, Trehalose 3%, Naaga 2.45% in a 12.5 mL ABAK® multi-dose bottle.

Sponsors

Laboratoires Thea
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Main Inclusion Criteria: * Informed consent signed and dated * Patient aged ≥ 18 years old * Well fitted contact lenses (CL) according to the investigator judgement * Daily wearer of any type of CL for a minimum of 5 days/week for 6 hours/day over at least the last month and is willing to continue to do so during the study * Patient with an Ocular Surface Disease Index (OSDI) score ≥ 18 * CLDEQ-8 score ≥ 12 Main

Exclusion criteria

* Far Best-Corrected Visual Acuity (BCVA) ≥+0.7 LogMar (e.g., ≤0.2 in decimal value or ≤20/100 Snellen equivalent or ≤50 ETDRS letters). * Severe blepharitis * Severe Meibomian gland dysfunction * Palpebral or nasolacrimal disorders * Dry eye associated with at least one of the following diseases/symptoms: ocular rosacea, Pterygium, Eyelid malposition, Corneal dystrophy, Ocular neoplasia, Filamentous keratitis, Corneal neovascularisation, Orbital radiotherapy, Cataract, Retinal disease.

Design outcomes

Primary

MeasureTime frameDescription
Change From Baseline in Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8) Total Score.CLDEQ- score is assessed at Day 1 and Day 36The primary endpoint is the change from baseline (Day 1) to Day 36 in the Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8) total score. CLDEQ-8 consists of 8 questions designed to measure dry eye symptoms specifically related to the use of contact lenses. The total score is obtained by adding the scores obtained for each answer. The final score is ranging from 1 to 37. 37 is the worst score.

Countries

Bulgaria

Participant flow

Participants by arm

ArmCount
T2769
One drop in each eye, from 3 to 6 times daily, at any time but only when patients are wearing their contact lenses. T2769: T2769: sodium hyaluronate 0.15%, Trehalose 3%, Naaga 2.45% in a 12.5 mL ABAK® multi-dose bottle.
34
Total34

Baseline characteristics

CharacteristicT2769
Age, Continuous39.7 years
STANDARD_DEVIATION 14
Race and Ethnicity Not Collected— Participants
Sex: Female, Male
Female
28 Participants
Sex: Female, Male
Male
6 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 34
other
Total, other adverse events
0 / 34
serious
Total, serious adverse events
0 / 34

Outcome results

Primary

Change From Baseline in Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8) Total Score.

The primary endpoint is the change from baseline (Day 1) to Day 36 in the Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8) total score. CLDEQ-8 consists of 8 questions designed to measure dry eye symptoms specifically related to the use of contact lenses. The total score is obtained by adding the scores obtained for each answer. The final score is ranging from 1 to 37. 37 is the worst score.

Time frame: CLDEQ- score is assessed at Day 1 and Day 36

ArmMeasureValue (MEAN)Dispersion
T2769Change From Baseline in Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8) Total Score.-12.6 score on a scaleStandard Deviation 5

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026